Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paliperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 16/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 15/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 0.75 |
| ▸ | ACHE | P22303 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paliperidone SCHEMBL11899798 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL20572022 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL436689 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL29409219 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL29377584 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL1667922 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL1831211 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL1119094 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL1443676 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR2CKCNH2ADRA1A | |
| Paliperidone SCHEMBL3074063 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR2CKCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13323 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| CN-122036594-A | Preparation method of paliperidone palmitate key intermediate | 北京莱瑞森医药科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4736842-A1 | IN SITU GEL FORMULATION AND PREPARATION METHOD THEREOF | ANXO Pharmaceutical Co., Ltd. (TW) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-3713986-B1 | COMPOSITION | REBIO TECH OY (FI) | 2026-04-01 | — | — | EP | claimed |
| CN-121570440-A | High-water permeability and high-adhesion pressure-sensitive adhesive patch matrix and preparation method and application thereof | 沈阳药科大学 | 2026-02-27 | — | — | CN | claimed |
| WO-2001034113-A2 | APPARATUS AND METHOD FOR PREPARING MICROPARTICLES | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1033987-A2 | AQUEOUS SUSPENSIONS OF SUBMICRON 9-HYDROXYRISPERIDONE FATTY ACID ESTERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-13 | — | — | EP | claimed |
| US-6077843-A | COMPRISING SUSTAINED RELEASE FORMULATIN FOR TREATING SCHIZOPHRENIA, NON-SCHIZOPHRENIC PSYCHOSES, BEHAVIOURAL DISTURBANCES ASSOCIATED WITH NEURODEGENERATIVE DISORDERS, E.G. IN DEMENTIA, BEHAVIOURAL DISTURBANCES IN MENTAL RETARDATION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-06-20 | — | — | US | claimed |
| WO-2000023057-A2 | ATYPICAL ANTIPHSYCHOTIC IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITOR FOR IMPROVING COGNITION | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-27 | — | — | WO | claimed |
| US-5916598-A | FIRST AND SECOND PHASES ARE COMBINED TO FORM AN EMULSION IN WHICH THE FIRST PHASE IS DISCONTINUOUS AND THE SECOND PHASE IS CONTINUOUS. THE PHASES ARE IMMERSED IN A QUENCH LIQUID. | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 1999-06-29 | — | — | US | claimed |
| WO-1999025354-A2 | AQUEOUS SUSPENSIONS OF SUBMICRON 9-HYDROXYRISPERIDONE FATTY ACID ESTERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-05-27 | — | — | WO | claimed |
| EP-0904063-A2 | MICROPARTICLES | Alkermes Controlled Therapeutics Inc. II (US) | 1999-03-31 | — | — | EP | claimed |
| US-5792477-A | EMULSIFICATION OF TWO PHASES; SEPARATION; WASHING; REDUCING LEVEL OF RESIDUAL SOLVENT | ALKERMES CONTROLLED THERAPEUTICS, INC. II (US) | 1998-08-11 | — | — | US | claimed |
| WO-1997041837-A2 | MICROPARTICLES | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 1997-11-13 | — | — | WO | claimed |
| US-5650173-A | Preparation of biodegradable microparticles containing a biologically active agent | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 1997-07-22 | — | — | US | claimed |